Skip to content
AnalystLens

ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 15, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 15, 2025
Period End
October 15, 2025
Security
ABT
In the record · 2016–202610-K1110-Q328-K131

ABT filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 131 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Oct ’17Oct ’17
  2. Material agreement8-K · Jun ’20Jun ’20
  3. Leadership change8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Nov ’24Nov ’24

01—Abstract

Summary

Summary of the 8-K filed October 15, 2025. Cited figures are marked; the original filing is the authoritative source.

Abbott Laboratories reported third-quarter 2025 results on October 15, 2025, with reported sales of $11.369 billiona, up 6.9% year over year.

Organic growth was 5.5%b, or 7.5% excluding COVID-19 testing-related sales, which have declined sharply as the pandemic transitioned to endemic demand. Growth was led by Medical Devices (up 14.8% reported, 12.5% organic), with double-digit gains in Diabetes Care, Electrophysiology, Rhythm Management, Heart Failure and Structural Heart. Nutrition grew 4.2% and Established Pharmaceuticals grew 7.5%, while Diagnostics declined 6.6% reported (down 7.8% organic, but up 0.4% excluding COVID-19 testing), with China volume-based procurement weighing on Core Laboratory results.

On a GAAP basis, third-quarter diluted EPS was $0.94c, flat year over year, and net earnings were $1.644 billion, down 0.1%. The GAAP result was held back by a higher tax rate of 24.6%, which includes roughly $160 million of adjustments tied to prior recognition of a significant non-cash deferred tax benefit. Adjusted diluted EPS was $1.30, up 7.4%, excluding $0.36 per share of specified items, primarily $420 million of intangible amortization plus restructuring and acquisition-related charges.

Operating margin was 18.1%d on a reported basis and 23.0% on an adjusted basis, a 40 basis point improvement. Management reaffirmed full-year 2025 organic sales growth guidance of 7.5% to 8.0% excluding COVID-19 testing (6.0% to 7.0% including it).

It reaffirmed the midpoint of adjusted EPS guidance and narrowed the range to $5.12 to $5.18, implying double-digit growth at the midpoint. Abbott also declared its 407th consecutive quarterly dividend of $0.59 per share, payable November 17, 2025, to holders of record on October 15, 2025.

02—Key points

Key Highlights

  1. Q3 2025 reported sales rose 6.9% to $11.369 billion; organic growth was 5.5% (7.5% excluding COVID-19 testing sales).
  2. Medical Devices was the main growth driver, up 14.8% reported and 12.5% organic, with Diabetes Care sales of $2.057 billion and continuous glucose monitor sales of $2.0 billion growing 20.5% reported.
  3. Diagnostics sales fell 6.6% reported and 7.8% organic, although excluding COVID-19 testing they rose 0.4%; COVID-19 testing sales dropped to $69 million from $265 million a year earlier.
  4. GAAP diluted EPS was $0.94, flat year over year, while adjusted diluted EPS was $1.30, up 7.4%, excluding $0.36 per share of specified items.
  5. GAAP tax rate rose to 24.6% from 15.2%, including about $160 million of adjustments related to prior recognition of a non-cash deferred tax benefit.
  6. Full-year 2025 organic sales growth guidance was reaffirmed at 7.5% to 8.0% excluding COVID-19 testing; adjusted EPS guidance midpoint was reaffirmed and narrowed to $5.12 to $5.18.
  7. Abbott declared its 407th consecutive quarterly dividend of $0.59 per share, payable November 17, 2025, and has increased its dividend for 53 consecutive years.

03—Questions

Frequently Asked Questions

  1. Why was GAAP EPS flat while adjusted EPS grew 7.4%?

    GAAP diluted EPS of $0.94 included $0.36 per share of specified items, mainly $420 million of intangible amortization, plus restructuring, acquisition-related and other charges. Excluding these, adjusted EPS rose to $1.30 from $1.21. GAAP results were also pressured by a higher tax rate of 24.6%, which includes about $160 million of adjustments related to a prior non-cash deferred tax benefit.

  2. What is driving growth in Medical Devices, and is it sustainable?

    Medical Devices sales rose 14.8% reported and 12.5% organic in Q3, led by double-digit growth in Diabetes Care, Electrophysiology, Rhythm Management, Heart Failure and Structural Heart. Continuous glucose monitors grew 20.5% reported. Sustainability depends on continued adoption of these products and on the company's pipeline, which management describes as differentiated; the filing does not give a forward-looking estimate of how long this growth rate will persist.

  3. Why did Diagnostics decline, and what is the outlook?

    Diagnostics fell 6.6% reported and 7.8% organic, largely because COVID-19 testing demand has declined sharply since the pandemic became endemic. Excluding COVID-19 testing, Diagnostics grew 0.4%. Core Laboratory growth was held back by challenging conditions in China, including volume-based procurement programs. The filing does not provide a specific Diagnostics forecast.

  4. Is the dividend safe, and what is the payout history?

    Abbott declared a quarterly dividend of $0.59 per share, its 407th consecutive quarterly payment, payable November 17, 2025, to shareholders of record on October 15, 2025. The company has increased its dividend for 53 consecutive years and is an S&P 500 Dividend Aristocrat. Given the 2025 adjusted EPS guidance of $5.12 to $5.18, the dividend is well covered on an adjusted basis, though the filing itself does not discuss payout ratio targets.

04—Continue

← View all 8-K filings